Co-Diagnostics, Inc. (CODX)
NASDAQ: CODX · Real-Time Price · USD
1.040
-0.030 (-2.80%)
Nov 20, 2024, 4:00 PM EST - Market closed

Company Description

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally.

The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.

It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus.

In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings.

The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Co-Diagnostics, Inc.
Co-Diagnostics logo
Country United States
Founded 2013
IPO Date Jul 12, 2017
Industry Medical Devices
Sector Healthcare
Employees 155
CEO Dwight Egan

Contact Details

Address:
2401 South Foothill Drive, Suite D
Salt Lake City, Utah 84109
United States
Phone (801) 438-1036
Website codiagnostics.com

Stock Details

Ticker Symbol CODX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001692415
CUSIP Number 189763105
ISIN Number US1897631057
Employer ID 46-2609396
SIC Code 3841

Key Executives

Name Position
Dwight H. Egan Chairman and Chief Executive Officer
Brian L. Brown CPA Chief Financial Officer and Company Secretary
Richard David Abbott President
Dr. Brent C. Satterfield Ph.D. Co-Founder and Member of Scientific Advisory Board
David Nielsen Chief Operating Officer
Dan Bohrer CPA Vice President of Finance and Accounting
Christopher Thurston Chief Technology Officer
Andrew Benson Head of Investor Relations
Dr. Mayuranki Almaula Senior Vice President of Overseas Operations and Strategic Alliances
Cameron Gundry Head of Commercialization LATAM/EUR

Latest SEC Filings

Date Type Title
Nov 8, 2024 8-K/A [Amend] Current report
Nov 7, 2024 10-Q Quarterly Report
Nov 7, 2024 8-K Current Report
Oct 18, 2024 424B5 Filing
Aug 30, 2024 8-K Current Report
Aug 8, 2024 10-Q Quarterly Report
Aug 8, 2024 8-K Current Report
Jul 16, 2024 DEF 14A Other definitive proxy statements
Jun 14, 2024 8-K Current Report
May 9, 2024 10-Q Quarterly Report